Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23276640 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL6622985 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL23499977 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL3347747 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL8890863 | 0.82 | KDM4E (0.70) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL30238199 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL9682990 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL5188827 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL24821261 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL350989 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1GAAHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111533180-B | Preparation method of large-particle carbon-doped cobaltosic oxide | 蒋达金 | 2022-07-19 | — | — | CN | claimed |
| CN-111533180-A | Preparation method of large-particle carbon-doped cobaltosic oxide | 蒋达金 | 2020-08-14 | — | — | CN | claimed |
| US-4333877-A | Substituted 2,7-dioxo-2,7-dihydrobenzo[1:2-b; 5:6-b1 ]difuran or -dipyrrole dyestuffs, their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-06-08 | — | — | US | claimed |
| CN-111533180-B | Preparation method of large-particle carbon-doped cobaltosic oxide | 蒋达金 | 2022-07-19 | — | — | CN | disclosed |
| CN-111533180-B | Preparation method of large-particle carbon-doped cobaltosic oxide | 蒋达金 | 2022-07-19 | — | — | CN | disclosed |
| CN-111533180-A | Preparation method of large-particle carbon-doped cobaltosic oxide | 蒋达金 | 2020-08-14 | — | — | CN | disclosed |
| CN-111533180-A | Preparation method of large-particle carbon-doped cobaltosic oxide | 蒋达金 | 2020-08-14 | — | — | CN | disclosed |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080020973-A1 | Assays for identification of topoisomerase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080020973-A1 | Assays for identification of topoisomerase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-01-24 | — | — | US | disclosed |
| US-5916916-A | USEFUL AS SELECTIVE ESTROGEN RECEPTOR MODULATORS. | ELI LILLY AND COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0729951-B1 | Naphthyl compounds, intermediates, compositions, and methods | LILLY CO ELI (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0835867-A1 | 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998008797-A1 | NAPHTHYL COMPOUNDS, INTERMEDIATES, COMPOSITIONS, AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0826679-A2 | Naphthyl compounds, intermediates, compositions, and method of use | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1997014685-A1 | PYRIMIDINE DERIVATIVES | GYÓGYSZERKUTATÓ INTÉZET KFT (HU) | 1997-04-24 | — | — | WO | disclosed |
| US-5574190-A | AROMATIC ETHER DERIVATIVES FOR TREATMENT OF HORMONE DEPENDENT CANCER SUCH AS BREAST CANCER | ELI LILLY AND COMPANY (US) | 1996-11-12 | — | — | US | disclosed |
| US-5567712-A | THERAPY FOR ENDOMETRIOSIS | ELI LILLY AND COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0729951-A1 | Naphthyl compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020973-A1 | Assays for identification of topoisomerase inhibitors | TOP1, TOP2A, TOP2B | KDM4E 2099/4885ALDH1A1 3092/4885GAA 301/4885 |
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | KDM4E 1854/4885ALDH1A1 1527/4885GAA 2633/4885 |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | PSEN2, PSEN1, ACHE | KDM4E 1658/4885ALDH1A1 412/4885GAA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.